Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Samantha Pozzi, MD, Diana Cirstea, M.D., Loredana Santo, MD, Doris M Nabikejje, Kishan Patel, Kathryn M Luly, Gaurav Gharti-Chhetry, Sonia Vallet, MD, Homare Eda, MD, PhD, Teru Hideshima, MD, Simon R Green, Kenneth C. Anderson, MD, David T. Scadden, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2999.

https://doi.org/10.1182/blood.V116.21.2999.2999

Published: 2010

Journal Articles

2′–Cyano–2′–Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.

Elisabeth J Walsby, Chiara Ghiggi, Ruth H Mackay, Simon R Green, Steven Knapper, Alan K Burnett

Blood (2009) 114 (22): 4153.

https://doi.org/10.1182/blood.V114.22.4153.4153

Published: 2009

Journal Articles

Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

Delfine Y.H. Hallaert, Rene Spijker, Margot Jak, Annelieke Jaspers, Ingrid A.M. Derks, Nuno L. Alves, Drs, Jan Paul de Boer, Daphne de Jong, MD, Simon R. Green, Rene A.W. van Lier, MD, PhD, Marinus H.J. van Oers, MD, PhD, Eric Eldering, PhD

Blood (2006) 108 (11): 2103.

https://doi.org/10.1182/blood.V108.11.2103.2103

Published: 2006

Journal Articles

The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.

Delfine Hallaert, Rene Spijker, Ingrid A.M. Derks, Margot Jak, MD, Bart de Goeij, Jan Paul de Boer, MD, PhD, Daphne de Jong, MD, PhD, Simon R. Green, Rene van Lier, MD, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2005) 106 (11): 2983.

https://doi.org/10.1182/blood.V106.11.2983.2983

Published: 2005

Journal Articles

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Noopur Raje, Shaji Kumar, Teru Hideshima, Aldo Roccaro, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Nikhil C. Munshi, Simon R. Green, Kenneth C. Anderson

Blood (2005) 106 (3): 1042–1047.

https://doi.org/10.1182/blood-2005-01-0320

Published: 2005

Journal Articles

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraishi, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Simon R. Green, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3359.

https://doi.org/10.1182/blood.V104.11.3359.3359

Published: 2004

NARROW

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

2′–Cyano–2′–Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.

Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

2′–Cyano–2′–Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.

Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only